Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. blood pressure lowering
Show results for
Products
Applications

Companies

News
Articles

Refine by
Date

  • Older

Blood Pressure Lowering Articles & Analysis

10 news found

Huateng Pharma Provides Orlistat Intermediates CAS NO 104801-96-9 Large Scale Services

Huateng Pharma Provides Orlistat Intermediates CAS NO 104801-96-9 Large Scale Services

When the activity of lipase is blocked, dietary triglycerides are not hydrolyzed into absorbable free fatty acids, but remain unchanged. Orlistat also helps lower blood pressure and prevents type 2 diabetes in obese people. Orlistat medication does not allow a person to regain lost weight and does not block fat absorption from non-fat foods and ...

ByHunan Huateng Pharmaceutical Co. Ltd.


Orchestra BioMed Announces Presentations at TCT 2021 of Positive Long-Term Clinical Results from the MODERATO II Study Showing the Significant Clinical Impact of BackBeat CNT on Isolated Systolic Hypertension and Pulse Pressure

Orchestra BioMed Announces Presentations at TCT 2021 of Positive Long-Term Clinical Results from the MODERATO II Study Showing the Significant Clinical Impact of BackBeat CNT on Isolated Systolic Hypertension and Pulse Pressure

BackBeat CNT treated patients experienced a mean reduction of 17.5 mmHg in office systolic blood pressure measured 24-months following therapy activation. Patients with Isolated Systolic Hypertension (ISH) treated with BackBeat CNT experienced clinically meaningful and statistically significant reductions of 7.4 mmHg in ambulatory systolic ...

ByOrchestra BioMed, Inc.


Orchestra BioMed Announces Peer-Reviewed Publication of MODERATO II Study Results Showing a Statistically Significant Reduction in Blood Pressure in Pacemaker-Indicated Patients Treated with BackBeat Cardiac Neuromodulation Therapy

Orchestra BioMed Announces Peer-Reviewed Publication of MODERATO II Study Results Showing a Statistically Significant Reduction in Blood Pressure in Pacemaker-Indicated Patients Treated with BackBeat Cardiac Neuromodulation Therapy

There were no significant differences in cardiac echo parameters between the BackBeat CNT and control groups. Diastolic blood pressure and heart rate did not change between the BackBeat CNT and control groups during the study period, a notable finding given the high rate of ISH in the study population and the challenge to reduce systolic blood ...

ByOrchestra BioMed, Inc.


Orchestra BioMed Announces Clinical Data Demonstrating a Significant and Sustained Reduction in Blood Pressure in MODERATO II Control Patients After Crossover to BackBeat Cardiac Neuromodulation Therapy

Orchestra BioMed Announces Clinical Data Demonstrating a Significant and Sustained Reduction in Blood Pressure in MODERATO II Control Patients After Crossover to BackBeat Cardiac Neuromodulation Therapy

Ambulatory Systolic Blood Pressure (aSBP) decreased by an average of 10.3 mmHg (p Office Systolic Blood Pressure (oSBP) decreased by an average of 13.1 and 20.9 mmHg at 6 and 12 months, respectively. ...

ByOrchestra BioMed, Inc.


Orchestra BioMed Announces Clinical Data Showing Significant and Sustained Reduction in Systolic Blood Pressure Out to Two Years with BackBeat Cardiac Neuromodulation Therapy

Orchestra BioMed Announces Clinical Data Showing Significant and Sustained Reduction in Systolic Blood Pressure Out to Two Years with BackBeat Cardiac Neuromodulation Therapy

The data demonstrated a clinically meaningful and statistically significant reduction of 16.6 mmHg in office Systolic Blood Pressure (oSBP) that was sustained out to two years. “These data provide evidence of significant long-term reductions in systolic blood pressure with a lower-than-expected rate of ...

ByOrchestra BioMed, Inc.


Orchestra BioMed to Present at the Innovation in Cardiovascular Interventions Meeting and the CSI Focus D-HF Congress

Orchestra BioMed to Present at the Innovation in Cardiovascular Interventions Meeting and the CSI Focus D-HF Congress

The presentations will also feature BackBeat™ Cardiac Neuromodulation Therapy for which recently presented double-blind, randomized clinical results demonstrated a statistically significant reduction of 24-hour ambulatory systolic blood pressure. Additional conference details can be found below. ICI Meeting 2019 Title: Virtue® Sirolimus-Eluting ...

ByOrchestra BioMed, Inc.


Orchestra BioMed Strengthens Management Team with Appointments of Expert Product Development Leaders Juan A. Lorenzo and Paul V. Goode, Ph.D.

Orchestra BioMed Strengthens Management Team with Appointments of Expert Product Development Leaders Juan A. Lorenzo and Paul V. Goode, Ph.D.

Paul Goode, Ph.D., an expert in implantable neuromodulation devices joins as vice president, product development, Bioelectronic Therapies and will play a leadership role in the further development of BackBeat™ Cardiac Neuromodulation Therapy (CNT™) for which late-breaking double-blind, randomized clinical results recently presented at TCT 2019 demonstrated a statistically significant ...

ByOrchestra BioMed, Inc.


Orchestra BioMed Announces Late-Breaking Clinical Results Showing BackBeat Cardiac Neuromodulation Therapy Drives Significant Reduction in Systolic Blood Pressure

Orchestra BioMed Announces Late-Breaking Clinical Results Showing BackBeat Cardiac Neuromodulation Therapy Drives Significant Reduction in Systolic Blood Pressure

“This is a particularly challenging at-risk population with a very high rate of isolated systolic hypertension and persistently elevated blood pressure despite multi-drug therapy. BackBeat CNT appears to be a promising treatment to significantly reduce systolic blood pressure and has a favorable risk benefit profile as the ...

ByOrchestra BioMed, Inc.


Sodexo offers meatless Monday option to promote health and wellness

Sodexo offers meatless Monday option to promote health and wellness

A diet rich in whole grains, legumes, vegetables, nuts, and fruits along with a regular exercise program is consistently associated with lower blood cholesterol levels, lower blood pressure, less obesity and consequently less heart disease, stroke, diabetes, cancer, and overall mortality according to scientific ...

By3BL Media


21 Jun 2010: NIH-supported study finds novel pathway May open doors for new blood pressure treatments

Researchers have found that increasing certain proteins in the blood vessels of mice, relaxed the vessels, lowering the animal’s blood pressure. ...

ByNational Institute of Environmental Health Sciences (NIEHS)

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT